NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the "Company†) today announced the successful completion of its acquisition of Halda Therapeutics OpCo, Inc. ("Halda†), a clinical-stage biotechnology company with a proprietary Regulated Induced Proximity TArgeting Chimera (RIPTACâ"¢) platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer, for $3.05 billion in cash. "This strategic milestone underscores our commitment to redefining c ...